Literature DB >> 31090117

Modern approaches for modelling dystonia and Huntington's disease in vitro and in vivo.

Olga A Zhunina1, Nikita G Yabbarov1, Alexander N Orekhov2,3, Alexey V Deykin4.   

Abstract

Dystonia associated with Huntington's disease, Parkinson's disease or other neurodegenerative diseases substantially affects patients' quality of life and is a major health problem worldwide. The above-mentioned diseases are characterized by neurodegeneration accompanied by motor and cognitive impairment and often have complex aetiology. A frequent feature of these conditions is the abnormal accumulation of protein aggregates within specific neuronal populations in the affected brain regions. Familial neurodegenerative diseases are associated with a number of genetic mutations. Identification of these mutations allowed creation of modern model systems for studying neurodegeneration, either in cultured cells or in model animals. Animal models, especially mouse models, have contributed considerably to improving our understanding of the pathophysiology of neurodegenerative diseases. These models have allowed study of the pathogenic mechanisms and development of new disease-modifying strategies and therapeutic approaches. However, due to the complex nature of these pathologies and the irreversible damage that they cause to the neural tissue, effective therapies against neurodegeneration remain to be elaborated. In this review, we provide an overview of cellular and animal models developed for studying neurodegenerative diseases, including Huntington's disease and dystonia of different origins.
© 2019 The Authors. International Journal of Experimental Pathology © 2019 International Journal of Experimental Pathology.

Entities:  

Keywords:  Huntington disease; dystonia; neurodegenerative disease models; neuroprotection

Mesh:

Year:  2019        PMID: 31090117      PMCID: PMC6540672          DOI: 10.1111/iep.12320

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  70 in total

1.  Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice.

Authors:  H Li; S H Li; A L Cheng; L Mangiarini; G P Bates; X J Li
Journal:  Hum Mol Genet       Date:  1999-07       Impact factor: 6.150

2.  Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death.

Authors:  J A Parker; J B Connolly; C Wellington; M Hayden; J Dausset; C Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

Authors:  R J Ferrante; O A Andreassen; B G Jenkins; A Dedeoglu; S Kuemmerle; J K Kubilus; R Kaddurah-Daouk; S M Hersch; M F Beal
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

4.  Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia.

Authors:  Melanie Hamann; Angelika Richter
Journal:  Eur J Pharmacol       Date:  2002-05-17       Impact factor: 4.432

5.  Subtle microstructural changes of the striatum in a DYT1 knock-in mouse model of dystonia.

Authors:  Chang-Hyun Song; Douglas Bernhard; Caroline Bolarinwa; Ellen J Hess; Yoland Smith; H A Jinnah
Journal:  Neurobiol Dis       Date:  2013-01-19       Impact factor: 5.996

Review 6.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

Authors:  Shi-Hua Li; Xiao-Jiang Li
Journal:  Trends Genet       Date:  2004-03       Impact factor: 11.639

Review 7.  Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases.

Authors:  Jean-Michel Verdier; Isabelle Acquatella; Corinne Lautier; Gina Devau; Stéphanie Trouche; Christelle Lasbleiz; Nadine Mestre-Francés
Journal:  Front Neurosci       Date:  2015-03-04       Impact factor: 4.677

8.  A putative Drosophila homolog of the Huntington's disease gene.

Authors:  Z Li; C A Karlovich; M P Fish; M P Scott; R M Myers
Journal:  Hum Mol Genet       Date:  1999-09       Impact factor: 6.150

9.  Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.

Authors:  Maria Armakola; Matthew J Higgins; Matthew D Figley; Sami J Barmada; Emily A Scarborough; Zamia Diaz; Xiaodong Fang; James Shorter; Nevan J Krogan; Steven Finkbeiner; Robert V Farese; Aaron D Gitler
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

10.  The BACHD Rat Model of Huntington Disease Shows Specific Deficits in a Test Battery of Motor Function.

Authors:  Giuseppe Manfré; Erik K H Clemensson; Elisavet I Kyriakou; Laura E Clemensson; Johanneke E van der Harst; Judith R Homberg; Huu Phuc Nguyen
Journal:  Front Behav Neurosci       Date:  2017-11-03       Impact factor: 3.558

View more
  3 in total

Review 1.  Modern approaches for modelling dystonia and Huntington's disease in vitro and in vivo.

Authors:  Olga A Zhunina; Nikita G Yabbarov; Alexander N Orekhov; Alexey V Deykin
Journal:  Int J Exp Pathol       Date:  2019-05-15       Impact factor: 1.925

Review 2.  Effects of Exercise on Skeletal Muscle Pathophysiology in Huntington's Disease.

Authors:  Bruno Trovato; Benedetta Magrì; Alessandro Castorina; Grazia Maugeri; Velia D'Agata; Giuseppe Musumeci
Journal:  J Funct Morphol Kinesiol       Date:  2022-05-11

Review 3.  Huntington's disease: nearly four decades of human molecular genetics.

Authors:  James F Gusella; Jong-Min Lee; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2021-10-01       Impact factor: 5.121

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.